- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04755673
Atrantil for Intestinal Bacterial Overgrowth
Open-Label Assessment of the Efficacy of Atrantil In the Treatment of Methane-Predominate Intestinal Bacterial Overgrowth
Study Overview
Status
Intervention / Treatment
Detailed Description
Intestinal microbial overgrowth is associated with multiple gastrointestinal symptoms. Most prevalent are gas-related symptoms (i.e. bloating, distention, increased flatus, constipation)
. Intestinal microbial overgrowth can currently be divided into two main subcategories: small intestinal bacterial overgrowth (SIBO) and intestinal methanogenic overgrowth (IMO). Both are most commonly detected via breath testing-a simple non-invasive study
- Despite the increasing prevalence of this disorder few evidence-based therapeutics currently exist. SIBO, identified by elevations in breath hydrogen, has been shown to respond to treatment with antibiotics including rifaximin and doxycycline in clinical trials
- However, IMO, detected by elevations in breath methane is a different disorder attributed to overgrowth of archaea which reside predominately in the colon
- Currently, there are no evidence-based treatments for IMO, and the American College of Gastroenterology guideline on the diagnosis and treatment of SIBO makes no specific recommendations regarding the treatment of this disorder.
Atrantil is a medical food composed of peppermint, quebracho tree bark, and horse chestnut.
These components are purported to reduce methane production, scavenge hydrogen (thus reducing the building blocks for methane), and potentially act as a cidal agent for methanogenic archaea. In a small randomized controlled-trial, Atrantil reduced bloating and constipation in a population of individuals with irritable bowel syndrome with constipation (IBS-C)
Given these initial results the investigators hypothesize that Atrantil may represent an inexpensive and safe treatment for patients with excessive methane production. Thus, the purpose of this study is to determine whether the holistic treatment, Atrantil, is beneficial for the treatment of IMO.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Medicine Digestive Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be able to provide informed consent
- Participants must be able to attend study visits
- Participants aged 18 years or greater
- Must have a diagnosis of Intestinal Methane Overgrowth based on North American Consensus/American College of Gastroenterology established cutoffs
- Participants must report current symptoms of bloating, distention, abdominal pain, abdominal discomfort and constipation
- Participant must be an established patient at Northwestern Memorial Hospital
Exclusion Criteria:
- Participants who are already taking Atrantil
- Participants who are pregnant or breast-feeding
- Participants who cannot tolerate or are unwilling to complete a hydrogen-methane breath test at week 4.
- Inability to attend all study visits and complete survey data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Atrantil (Medical Food)
All participants in the trial will take two capsules of Atrantil three times a day for 28 days.
|
All participants will be given 28 days supply of Atrantil.
The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinical symptoms of Intestinal Methane Overgrowth as measured by daily Numeric Rating Scale (NRS) measuring pain, bloating, distention, and discomfort.
Time Frame: Daily for 28 days
|
Numeric Rating Scale is a four-item scale measuring the severity of pain, bloating, distention, and discomfort on a scale of 1 to 10 for each measure.
Higher scores indicate a higher level of symptom severity.
Lower scores indicate a lower level of symptom severity.
|
Daily for 28 days
|
Change in clinical symptoms of Intestinal Methane Overgrowth as measured by Patient Reported Outcome Measures Information Systems Gastrointestinal Symptoms Scale (PROMIS-GI)
Time Frame: Change from Baseline at four weeks.
|
PROMIS GI Scales is a collection of eight categories of GI-symptoms (Belly pain, Bowel Incontinence, Constipation, Diarrhea, Disrupted Swallowing, Gas and Bloating, Nausea and Vomiting, and Acid reflux) Higher scores indicate a higher level of symptom severity.
Lower scores indicate a lower level of symptom severity.
|
Change from Baseline at four weeks.
|
Change in clinical symptoms of Intestinal Methane Overgrowth as measured by the Bristol Stool Scale (BSS)
Time Frame: Change from Baseline at four weeks.
|
BSS is a clinical tool that divides feces into 7 categories along the continuum severe constipation to severe diarrhea to demonstrate the effectiveness of a treatment
|
Change from Baseline at four weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of life as measured by Short Form- 12.
Time Frame: Change from Baseline at four weeks.
|
SF-12 scale is a generic, multipurpose short-form survey with 12 questions selected from the SF-36 Health Survey to evaluate overall health-related quality of life.
Answers are combined, scored and weighted into mental and physical functioning component scales.
The scores for each scale range from 0 to 100.
A higher value indicates a better quality of life of the patient.
|
Change from Baseline at four weeks.
|
Change in Quality of life as measured by the PROMIS-Global Health (PROMIS-GH)
Time Frame: Change from Baseline at four weeks.
|
PROMIS® Global Health Short Form (10 items).
The 10 global health items include ratings of the five core PROMIS domains.
It includes the most widely used self-rated health item (global01).
PROMIS® includes a single item that provides a pure rating of physical health (global03) and another item for mental health (global04).
Also included is an overall quality of life item (global02).
The remaining items provide global ratings of physical function (global06), fatigue (global08), pain (global07), emotional distress (global10), and social health (global05 and global09).
The 10 PROMIS® Global Health items each have 5 response choices, with the exception of the common 11-point pain intensity item ("How would you rate your pain on average" with 0=No pain and 10=Worst imaginable pain).
Global 1-5, 9 range from 5 (Excellent) to 1 (Poor), with higher numbers meaning greater health.
Certain items are restored (Global 7 such that 5=0 no pain, and 1=10 worst pain), Global8 (5=None, 1=Very Severe),
|
Change from Baseline at four weeks.
|
Change in methane as measured by hydrogen methane breath-test pre and post-treatment.
Time Frame: Post-Treatment (+-3 days)
|
Methane levels equal to or more than 10 parts per million are considered abnormal and positive for intestinal methane overgrowth.
Methane levels under 10 are considered normal and negative for intestinal methane overgrowth.
|
Post-Treatment (+-3 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Darren Brenner, MD, Northwestern Memorial Hospital/Feinberg School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00212557
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
University of ViennaCompleted
-
GlaxoSmithKlineCompletedIrritable Bowel Syndrome (IBS) | Irritable ColonUnited States
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
Clinical Trials on Atrantil (Medical Food)
-
Abbott NutritionCompleted
-
Romanian Society for Enteral and Parenteral NutritionNot yet recruitingTrauma | Gastroparesis | Muscle Loss | Metabolism | Nutritional Deficiency | Protein Malnutrition | Calorie Malnutrition ProteinRomania
-
Abbott NutritionCompletedHip FractureRussian Federation
-
Faeth TherapeuticsRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic AdenocarcinomaUnited States
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Faeth TherapeuticsWithdrawnMetastatic Colorectal CancerUnited States
-
Targeted Medical PharmaUnknownDiabetic Neuropathy | Chemotherapy Induced Neuropathy | HIV Neuropathy | Trauma Induced NeuropathyUnited States
-
Pendulum TherapeuticsTerminatedType 2 Diabetes MellitusIreland
-
Solarea Bio, IncRecruiting
-
Solarea Bio, IncHebrew SeniorLifeCompleted